NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) has reported positive Phase 2a results for its lead drug candidate NEO100 in recurrent brain cancer, a development that could reshape the treatment landscape for this difficult-to-treat disease. The data, released in conjunction with Stonegate Capital Partners' updated coverage, show that NEO100 achieved a six-month progression-free survival (PFS) rate of 48.9% as measured by RANO 2.0 criteria using Kaplan-Meier estimation, compared to a pre-specified benchmark of 20% (p=0.0047). More notably, median overall survival reached 26.09 months, a figure that stands in stark contrast to the six to nine months typically seen with current salvage therapies for recurrent brain cancer.
The survival signal is particularly compelling because it suggests a meaningful clinical benefit beyond what is currently available. While the PFS endpoint was met, the overall survival data may be the more critical indicator of NEO100's potential. Management noted that current salvage therapy offers only six to nine months of survival, making NEO100's median OS of over two years a potentially transformative outcome. However, the company acknowledges that confirmation in a randomized controlled trial is necessary before this can be considered a definitive advance.
The positive readout positions NEO100 for a potential registrational program. NeOnc intends to request a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss the design and endpoints for a registrational trial, as well as the potential approval pathway. This meeting is a critical near-term catalyst, as FDA alignment will determine the regulatory route and could accelerate the path to market. The company also reported that NEO212, its second clinical asset, has gained regulatory momentum with Phase 2 CMC clearance and FDA feedback indicating a potential accelerated approval pathway.
Beyond the clinical data, the investment case for NeOnc is broadening. NEO100 is also being investigated in meningioma and pediatric brain tumors, while NEO212 offers a differentiated second program. This platform breadth increases long-term optionality, although funding remains a key consideration as development activity expands. In the second quarter of 2026, R&D expenses increased to $2.6 million from $0.7 million year-over-year, reflecting the accelerated clinical development.
Stonegate Capital Partners, which provides investor relations and equity research services, updated its coverage on NeOnc following the announcement. The research firm highlighted the favorable tolerability profile of NEO100, with no major toxicities reported, which supports the potential for chronic, patient-friendly treatment. This safety profile, combined with the efficacy data, strengthens the case for NEO100 as a potential standard of care in recurrent brain cancer.
For more information on the full announcement, including downloadable images and bios, click here.
